This question is particularly relevant with the passage of the Inflation Reduction Act (IRA) and the requirement that CMS negotiate a ‘maximum fair price’ for drugs with the biggest impact on Medicare’s bottom line. A Health Affairs Forefront paper by Lin et al. (2023) compares how drug price negotiation differs between Canada, France, Germany and the US. A helpful table is below, but do read the whole article here.
![](https://www.healthcare-economist.com/wp-content/uploads/2023/12/drug_price_negotiatoin-711x1024.png)